Role of the plasma membrane leaflets in drug uptake and multidrug resistance.
The present study aimed to investigate the role played by the leaflets of the plasma membrane in the uptake of drugs into cells and in their extrusion by P-glycoprotein and multidrug resistance-associated protein 1. Drug accumulation was monitored by fluorescence resonance energy transfer from trimethylammonium-diphenyl-hexatriene (TMA-DPH) located at the outer leaflet to a rhodamine analog. Uptake of dye into cells whose mitochondria had been inactivated was displayed as two phases of TMA-DPH fluorescence quenching. The initial phase comprised a rapid drop in fluorescence that was neither affected by cooling the cells on ice, nor by activity of mitochondria or ABC transporters. This phase reflects the association of dye with the outer leaflet of the plasma membrane. The subsequent phase of TMA-DPH fluorescence quenching occurred in drug-sensitive cell lines with a half-life in the range 20-40 s. The second phase of fluorescence quenching was abolished by incubation of the cells on ice and was transiently inhibited in cells with active mitochondria. Thus, the second phase of fluorescence quenching reflects the accumulation of dye in the cytoplasmic leaflet of the plasma membrane, presumably as a result of flip-flop of dye across the plasma membrane and slow diffusion from the inner leaflet into the cells. Whereas activity of P-glycoprotein prevented the second phase of fluorescence quenching, the activity of multidrug resistance-associated protein 1 had no effect on this phase. Thus, P-glycoprotein appears to pump rhodamines from the cytoplasmic leaflet either to the outer leaflet or to the outer medium.
Katzir
Hagar
H
Department of Biology, The Technion-Israel Institute of Technology, Haifa, Israel.
Yeheskely-Hayon
Daniella
D
Regev
Ronit
R
Eytan
Gera D
GD
D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001692:Biological Transport; D045744:Cell Line, Tumor; D002462:Cell Membrane / Q000187:drug effects / Q000378:metabolism; D004161:Diphenylhexatriene / Q000031:analogs & derivatives* / Q000494:pharmacology; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D006801:Humans; D007938:Leukemia / Q000188:drug therapy; D027425:ATP-Binding Cassette, Sub-Family C Proteins / Q000378:metabolism*; D012235:Rhodamines / Q000494:pharmacology; D013050:Spectrometry, Fluorescence
D000970:Antineoplastic Agents; D004161:Diphenylhexatriene; D027425:ATP-Binding Cassette, Sub-Family C Proteins; D012235:Rhodamines; C401833:tetramethylrhodamine methyl ester; C033628:1-(4-(trimethylamino)phenyl)-6-phenylhexa-1,3,5-triene